Treatment | n | EC50 | Emax |
---|---|---|---|
μM | % of control | ||
Vehicle | 6 | 0.51 ± 0.06 | |
10-min 5-HT | 6 | 0.48 ± 0.05 | 61 ± 4.5 |
2-h 5-HT | 6 | 0.47 ± 0.10 | 24 ± 8.2 |
24-h 5-HT | 6 | 0.48 ± 0.20 | 26 ± 4.4 |
Vehicle | 4 | 0.54 ± 0.09 | |
10-min ketanserin | 4 | 0.80 ± 0.18 | 54 ± 4.2 |
30-min ketanserin | 4 | 0.83 ± 0.18 | 63 ± 5.6 |
2-h ketanserin | 4 | 0.55 ± 0.08 | 66 ± 6.9 |
Cells were treated with 5-HT (10 μM) and ketanserin (50 nM) for indicated times. Accumulation of [3H]IP was measured in triplicate after a 20-min incubation with quipazine, as described in Fig. 1. Shown are the mean ± S.E.M. EC50 values were analyzed by analysis of variance.